Arrowhead Net Income vs Total Revenue Analysis

ARWR Stock

USD 26.15 5.10 24.23%

Arrowhead Pharmaceuticals financial indicator trend analysis is way more than just evaluating Arrowhead Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Arrowhead Pharmaceuticals is a good investment. Please check the relationship between Arrowhead Pharmaceuticals Net Income and its Total Revenue accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arrowhead Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing.

To learn how to invest in Arrowhead Stock, please use our How to Invest in Arrowhead Pharmaceuticals guide.

Net Income vs Total Revenue

Net Income vs Total Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Arrowhead Pharmaceuticals Net Income account and Total Revenue. At this time, the significance of the direction appears to have no relationship.

The correlation between Arrowhead Pharmaceuticals' Net Income and Total Revenue is 0.06. Overlapping area represents the amount of variation of Net Income that can explain the historical movement of Total Revenue in the same time period over historical financial statements of Arrowhead Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Arrowhead Pharmaceuticals' Net Income and Total Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Income of Arrowhead Pharmaceuticals are associated (or correlated) with its Total Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Revenue has no effect on the direction of Net Income i.e., Arrowhead Pharmaceuticals' Net Income and Total Revenue go up and down completely randomly.

Correlation Coefficient

0.06

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Net Income

Net income is one of the most important fundamental items in finance. It plays a large role in Arrowhead Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Arrowhead Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.

Total Revenue

Total revenue comprises all receipts Arrowhead Pharmaceuticals generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Most indicators from Arrowhead Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Arrowhead Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arrowhead Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing.

To learn how to invest in Arrowhead Stock, please use our How to Invest in Arrowhead Pharmaceuticals guide.At this time, Arrowhead Pharmaceuticals' Tax Provision is relatively stable compared to the past year. As of 11/29/2024, Enterprise Value is likely to grow to about 3.3 B, while Selling General Administrative is likely to drop slightly above 93.8 M.

	2021	2022	2023	2024 (projected)
Gross Profit	243.2M	240.7M	3.6M	3.4M
Total Revenue	243.2M	240.7M	3.6M	3.4M

Gross Profit Total Revenue

Arrowhead Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Common Stock	Current Deferred Revenue	Non Current Liabilities Total
Total Assets		0.92	0.89	0.85	0.44	0.91	0.15	-0.95	0.52	0.39	0.99	0.34	0.99	0.16	0.75	0.84	-0.74	0.78	0.98	0.95	0.9	0.99	0.66	0.2	0.25	0.92
Short Long Term Debt Total	0.92		0.91	0.72	0.19	0.98	0.4	-0.93	0.64	0.18	0.92	0.41	0.91	-0.09	0.63	0.72	-0.92	0.85	0.92	0.96	0.96	0.91	0.7	0.27	0.05	0.95
Other Current Liab	0.89	0.91		0.64	0.19	0.86	0.38	-0.88	0.39	0.17	0.91	0.68	0.87	0.02	0.64	0.72	-0.89	0.95	0.9	0.94	0.81	0.87	0.51	0.55	0.17	0.94
Total Current Liabilities	0.85	0.72	0.64		0.59	0.67	-0.2	-0.73	0.57	0.65	0.86	0.21	0.82	0.49	0.68	0.8	-0.48	0.63	0.81	0.74	0.68	0.83	0.81	0.13	0.62	0.66
Total Stockholder Equity	0.44	0.19	0.19	0.59		0.13	-0.59	-0.25	0.4	0.8	0.44	-0.12	0.43	0.48	0.52	0.6	0.09	0.19	0.42	0.14	0.17	0.43	0.36	-0.1	0.52	0.06
Property Plant And Equipment Net	0.91	0.98	0.86	0.67	0.13		0.46	-0.96	0.6	0.09	0.9	0.28	0.91	-0.12	0.61	0.68	-0.87	0.74	0.91	0.96	0.99	0.91	0.61	0.11	-0.09	0.96
Net Debt	0.15	0.4	0.38	-0.2	-0.59	0.46		-0.32	0.12	-0.81	0.2	0.21	0.11	-0.38	-0.14	-0.14	-0.58	0.3	0.18	0.37	0.44	0.11	-0.16	0.12	-0.62	0.45
Retained Earnings	-0.95	-0.93	-0.88	-0.73	-0.25	-0.96	-0.32		-0.53	-0.21	-0.93	-0.3	-0.95	0.03	-0.77	-0.82	0.79	-0.74	-0.97	-0.95	-0.94	-0.95	-0.59	-0.14	-0.04	-0.94
Accounts Payable	0.52	0.64	0.39	0.57	0.4	0.6	0.12	-0.53		0.3	0.55	-0.13	0.49	-0.03	0.43	0.51	-0.53	0.43	0.53	0.45	0.66	0.49	0.6	-0.15	-0.04	0.41
Cash	0.39	0.18	0.17	0.65	0.8	0.09	-0.81	-0.21	0.3		0.35	0.06	0.41	0.38	0.52	0.58	0.03	0.24	0.36	0.17	0.1	0.42	0.59	0.09	0.7	0.09
Non Current Assets Total	0.99	0.92	0.91	0.86	0.44	0.9	0.2	-0.93	0.55	0.35		0.39	0.96	0.23	0.72	0.82	-0.76	0.82	0.97	0.94	0.89	0.96	0.64	0.25	0.29	0.91
Non Currrent Assets Other	0.34	0.41	0.68	0.21	-0.12	0.28	0.21	-0.3	-0.13	0.06	0.39		0.32	0.0	0.25	0.3	-0.59	0.79	0.36	0.48	0.17	0.31	0.23	0.98	0.37	0.5
Cash And Short Term Investments	0.99	0.91	0.87	0.82	0.43	0.91	0.11	-0.95	0.49	0.41	0.96	0.32		0.1	0.76	0.84	-0.71	0.74	0.98	0.94	0.89	1.0	0.67	0.16	0.22	0.91
Net Receivables	0.16	-0.09	0.02	0.49	0.48	-0.12	-0.38	0.03	-0.03	0.38	0.23	0.0	0.1		0.12	0.15	0.25	0.03	0.08	0.03	-0.1	0.11	0.07	0.03	0.74	-0.05
Common Stock Total Equity	0.75	0.63	0.64	0.68	0.52	0.61	-0.14	-0.77	0.43	0.52	0.72	0.25	0.76	0.12		0.93	-0.45	0.57	0.83	0.64	0.6	0.76	0.51	0.16	0.28	0.6
Common Stock Shares Outstanding	0.84	0.72	0.72	0.8	0.6	0.68	-0.14	-0.82	0.51	0.58	0.82	0.3	0.84	0.15	0.93		-0.51	0.67	0.9	0.72	0.67	0.84	0.64	0.22	0.39	0.67
Inventory	-0.74	-0.92	-0.89	-0.48	0.09	-0.87	-0.58	0.79	-0.53	0.03	-0.76	-0.59	-0.71	0.25	-0.45	-0.51		-0.88	-0.74	-0.87	-0.84	-0.71	-0.55	-0.47	0.09	-0.89
Other Current Assets	0.78	0.85	0.95	0.63	0.19	0.74	0.3	-0.74	0.43	0.24	0.82	0.79	0.74	0.03	0.57	0.67	-0.88		0.79	0.84	0.68	0.74	0.57	0.71	0.3	0.83
Other Stockholder Equity	0.98	0.92	0.9	0.81	0.42	0.91	0.18	-0.97	0.53	0.36	0.97	0.36	0.98	0.08	0.83	0.9	-0.74	0.79		0.93	0.9	0.98	0.63	0.21	0.2	0.91
Total Liab	0.95	0.96	0.94	0.74	0.14	0.96	0.37	-0.95	0.45	0.17	0.94	0.48	0.94	0.03	0.64	0.72	-0.87	0.84	0.93		0.92	0.94	0.63	0.31	0.14	0.99
Property Plant And Equipment Gross	0.9	0.96	0.81	0.68	0.17	0.99	0.44	-0.94	0.66	0.1	0.89	0.17	0.89	-0.1	0.6	0.67	-0.84	0.68	0.9	0.92		0.9	0.62	0.01	-0.11	0.92
Total Current Assets	0.99	0.91	0.87	0.83	0.43	0.91	0.11	-0.95	0.49	0.42	0.96	0.31	1.0	0.11	0.76	0.84	-0.71	0.74	0.98	0.94	0.9		0.67	0.15	0.22	0.91
Short Term Debt	0.66	0.7	0.51	0.81	0.36	0.61	-0.16	-0.59	0.6	0.59	0.64	0.23	0.67	0.07	0.51	0.64	-0.55	0.57	0.63	0.63	0.62	0.67		0.16	0.46	0.56
Common Stock	0.2	0.27	0.55	0.13	-0.1	0.11	0.12	-0.14	-0.15	0.09	0.25	0.98	0.16	0.03	0.16	0.22	-0.47	0.71	0.21	0.31	0.01	0.15	0.16		0.42	0.33
Current Deferred Revenue	0.25	0.05	0.17	0.62	0.52	-0.09	-0.62	-0.04	-0.04	0.7	0.29	0.37	0.22	0.74	0.28	0.39	0.09	0.3	0.2	0.14	-0.11	0.22	0.46	0.42		0.05
Non Current Liabilities Total	0.92	0.95	0.94	0.66	0.06	0.96	0.45	-0.94	0.41	0.09	0.91	0.5	0.91	-0.05	0.6	0.67	-0.89	0.83	0.91	0.99	0.92	0.91	0.56	0.33	0.05

Click cells to compare fundamentals

Arrowhead Pharmaceuticals Account Relationship Matchups

Arrowhead Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	522.5M	710.1M	691.9M	765.6M	1.1B	1.2B
Other Current Liab	32.8M	33.3M	100.4M	58.2M	85.4M	89.7M
Total Current Liabilities	40.7M	146.5M	74.1M	105.5M	103.2M	108.3M
Total Stockholder Equity	461.8M	408.8M	106.0M	271.3M	185.4M	93.8M
Property Plant And Equipment Net	47.0M	66.0M	168.6M	335.6M	431.3M	452.9M
Net Debt	(122.4M)	(158.9M)	(26.4M)	4.3M	14.7M	15.4M
Retained Earnings	(503.8M)	(644.7M)	(820.8M)	(1.0B)	(1.6B)	(1.5B)
Accounts Payable	6.8M	9.5M	2.9M	35.9M	11.4M	12.0M
Cash	143.6M	184.4M	108.0M	110.9M	102.7M	53.4M
Non Current Assets Total	200.1M	325.6M	315.5M	346.0M	444.3M	466.5M
Non Currrent Assets Other	265.4K	272K	29.1M	210K	4.5M	4.7M
Cash And Short Term Investments	315.5M	367.8M	376.4M	403.6M	681.0M	715.0M
Net Receivables	327.4K	661.4K	845.7K	10.3M	1.4M	0.0
Common Stock Total Equity	187.9K	194.7K	197K	198K	227.7K	239.1K
Common Stock Shares Outstanding	100.7M	103.7M	105.4M	106.8M	119.8M	125.8M
Liabilities And Stockholders Equity	522.5M	710.1M	691.9M	765.6M	1.1B	1.2B
Inventory	3.3M	4.3M	4.4M	(21.6M)	(19.5M)	(18.5M)
Other Current Assets	6.0M	6.6M	27.5M	15.9M	14.5M	15.2M
Other Stockholder Equity	965.4M	1.1B	1.2B	1.3B	1.8B	1.9B
Total Liab	60.7M	301.3M	586.0M	478.4M	845.6M	887.8M
Property Plant And Equipment Gross	47.0M	88.9M	110.3M	377.5M	434.1M	455.8M
Total Current Assets	322.4M	384.6M	376.4M	419.5M	695.5M	730.2M
Accumulated Other Comprehensive Income	18.4K	(69K)	(136K)	(3.2M)	4.8M	5.0M
Short Term Debt	1.1M	4.5M	5.6M	9.7M	6.3M	6.7M
Common Stock	194.7K	197K	106.0M	200K	217K	206.2K
Current Deferred Revenue	19.3M	111.1M	74.1M	866K	995.9K	946.1K
Non Current Liabilities Total	20.0M	154.8M	511.9M	372.9M	742.4M	779.5M
Property Plant Equipment	30.9M	48.7M	110.3M	335.6M	385.9M	405.2M
Other Assets	68.9M	96.8M	218K	210K	241.5K	229.4K
Short Term Investments	171.9M	183.4M	268.4M	292.7M	578.3M	607.2M
Intangible Assets	15.4M	13.7M	12.0M	10.3M	8.6M	10.2M
Other Liab	8.7M	41.4M	190.3M	56.0M	64.3M	67.6M
Net Tangible Assets	446.4M	395.2M	398.5M	261.1M	300.2M	202.9M

Pair Trading with Arrowhead Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Arrowhead Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Arrowhead Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving against Arrowhead Stock

0.45	BHC	Bausch Health Companies	Pair Corr
0.36	EWTX	Edgewise Therapeutics	Pair Corr
0.36	GANX	Gain Therapeutics	Pair Corr
0.34	HCM	HUTCHMED DRC	Pair Corr

The ability to find closely correlated positions to Arrowhead Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Arrowhead Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Arrowhead Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Arrowhead Pharmaceuticals to buy it.

The correlation of Arrowhead Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Arrowhead Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Arrowhead Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Arrowhead Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Arrowhead Stock Analysis

When running Arrowhead Pharmaceuticals' price analysis, check to measure Arrowhead Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arrowhead Pharmaceuticals is operating at the current time. Most of Arrowhead Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Arrowhead Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arrowhead Pharmaceuticals' price. Additionally, you may evaluate how the addition of Arrowhead Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC